Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation

• Published in: The American heart journal Vol. 212; pp. 113 - 119
• Main Authors: Peterson, Eric D., Ashton, Veronica, Chen, Yen-Wen, Wu, Bingcao, Spyropoulos, Alex C.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2019; Elsevier Limited
• Subjects: Anticoagulants; Anticoagulants - economics; Anticoagulants - therapeutic use; Atrial Fibrillation - complications; Atrial Fibrillation - drug therapy; Atrial Fibrillation - epidemiology; Bleeding; Body mass; Body mass index; Body size; Body weight; Cardiac arrhythmia; Codes; Committees; Comorbidity; Confidence intervals; Costs; Diabetes; Diagnostic systems; Drug Costs; Embolism; Embolisms; Factor Xa Inhibitors - economics; Female; Fibrillation; Follow-Up Studies; Health care; Health risks; Heart failure; Heart transplantation; Heart valves; Humans; Hypertension; Identification methods; Incidence; Ischemia; Male; Medicare; Middle Aged; Morbidity - trends; Obesity; Obesity, Morbid - complications; Obesity, Morbid - epidemiology; Patients; Pharmacy; Population; Prescription drugs; Resource utilization; Retrospective Studies; Rivaroxaban - economics; Rivaroxaban - therapeutic use; Statistical analysis; Statistical models; Stenosis; Stroke; Stroke - epidemiology; Stroke - etiology; Stroke - prevention & control; Survival Rate - trends; United States - epidemiology; Warfarin; Warfarin - economics; Warfarin - therapeutic use; United States

There are limited data regarding clinical outcomes and healthcare resource utilization of direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) who are morbidly obese (body mass index >40 kg/m2 or body weight >120 kg). Using data from 2 US healthcare claims databases, we...